FDA Guidance expands environmental perspective

Share this article:

The FDA is tweaking its environmental impact guidance. Regulatory Focus reports that while required Environmental Assessments have been around for drugs since it issued its 1998 draft guidance, the guidance is a little dated in that it does not cover genetic therapy / biotech treatments.

RF notes that the new guidance, named Determining the Need for and Content of Environmental Assessments for Gene  Therapies, Vectored Vaccines and Related Recombinant Viral or Microbial Products “is meant to change that.”

These rules apply to items that require Biologics License Applications, known as BLAs, which accompany treatments submitted for FDA review.

RF notes the Food and Drug Administration is asking BLA-submitting drugmakers to include information such as descriptions of the substance and byproducts “that might find their way into the environment,” and “what effects could transgene expression or exposure have outside of the target populations?”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.